Compare Eli Lilly And Co (LLY) vs Omnicom Group Inc. (OMC) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Omnicom (OMC) trades at $82.36, up 0.77% with a bullish technical outlook and strong cash flow generation. The stock shows attractive valuation metrics with a P/E of 12.16 and P/S of 0.95, though 2025 saw a net loss of $54.5 million despite revenue growth to $17.27 billion. Recent developments include major client wins with IBM and Netflix partnerships, positioning the company for future growth in digital advertising.

OMC presents a compelling value opportunity with 28% upside to the $105.75 consensus price target, supported by dividend payments and institutional confidence. Key risks include intense industry competition and the need to sustain profitability improvements after the 2025 loss. The upcoming Q2 2026 earnings report on July 28 will be critical for validating the company's turnaround trajectory.